Roche Registers Fresh Win For New Flu Drug
Executive Summary
Ahead of an FDA decision scheduled for December 24, the Swiss major's baloxivir has improved influenza symptoms versus placebo, and to a lesser extent Roche's own Tamiflu, in people at high risk of serious complications from the virus.
You may also be interested in...
Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta
The latest drug development news and highlights from our US FDA Performance Tracker.
Roche's Xofluza Reduces Flu Symptoms In Children
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.
Keeping Track: US FDA Clears Novel Flu Treatment Xofluza, Boosts Trintellix Label With Sexual Dysfunction Data
The latest drug development news and highlights from our FDA Performance Tracker.